FLCCC Doctor Files Lawsuit Against Norfolk Hospital Because They Banned Ivermectin For C-19 Treatment!
FLCCC, co-chief Medical Officer Dr. Paul Marik filed a lawsuit against Santara Norfolk General Hospital.
His suit represents a response to Santara’s policy for banning the Ivermectin use for coronavirus treatment.
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
Dr. Maril is a director of the hospital’s critical care unit and contends the policy will result in needless deaths.
Norfolk doctor files lawsuit against Sentara on ban of Ivermectin use to treat COVID-19 https://t.co/HVvNQCWkDK pic.twitter.com/1Z5ZTtbZ5s
— WTKR News 3 (@WTKR3) November 11, 2021
Dr. Paul Marik: "Patients at Sentara Norfolk General Hospital are Dying Needlessly."
Lawsuit filed as hospital handcuffs doctors' ability to save dying COVID-19 patients.https://t.co/gwi7fQ3Ult pic.twitter.com/otsDrQcClh
— CuriousRabitt 🐇🧐🇮🇪 (@ApocalypseBar_B) November 10, 2021
WTKR 3 covered this story:
In this lawsuit, Doctor Paul Marik , the director of the hospital’s critical care unit, says Sentara’s ban of its use to treat patients with Ivermectin is deadly, and against the law.
Ivermectin is an anti-parasitic drug, widely used to treat worms in horses and cows, that has been at the center of controversy over COVID-19 care.
In the 80 page document, Dr. Marik said Sentara issued a directive to doctors last month banning the use of including Ivermectin to treat COVID-19 patients, unless they were part of a clinical trial.
He also made a claim in the lawsuit that said Sentara’s policy may have led to the deaths of four of his patients who were never given the opportunity to learn of or be treated with potentially life-saving medicines.
Dr. Marik’s of Ivermectin was the subject of Jessica Larche’s investigation in September..
Dr. Marik and his international group of doctors point to a list of smaller studies that suggest the drug is safe and effective at treating COVID-19.
Other doctors say there needs to be more data for there to be bigger clinical trials.
Santara’s policy stems from an article retraction of an FLCCC paper from the Journal of Intensive Care Medicine.
We read that the coronavirus mortality rate from the MATH+ protocol was 6.1%.
The hospital claimed that the death rate in patients getting all four MATH+ protocols was 28%. The hospital’s notice led to the retraction of the paper, and the policy banned the use of this drug for the virus treatment.
Authors claimed mortality rate under MATH+ protocol was 6.1%. But Sentara Norfolk General Hospital data shows mortality in patients receiving at least 1 of the MATH+ protocols was 24.7%. In patients receiving all four MATH+ protocols it was 28%. pic.twitter.com/JgprDfRZx1
— Elisabeth Bik (@MicrobiomDigest) November 9, 2021
Thread re: retraction of the FLCCC paper from the Journal of Intensive Care Medicine
It is unfortunate that JICM retracted an entire paper based on their refusal to accept an update to 1 section of data that had little relevance to the focus or conclusions of the paper (1/8)— Pierre Kory, MD MPA (@PierreKory) November 11, 2021
Using Sentara's method, they came up with a 10% mortality – STILL FAR LESS than the 23% U.S hospital mortality average average we were loosely comparing it to. (4/8)
— Pierre Kory, MD MPA (@PierreKory) November 11, 2021
We then provided the only follow-up data we had – JICM refused to accept. We then offered to retract the entire section with the old Sentara data – JICM refused. The conclusion of the paper (it was a RATIONALE paper) still stands without the Sentara data even being included. 6/8
— Pierre Kory, MD MPA (@PierreKory) November 11, 2021
If medical research is there just to serve in supporting mainstream collective thinking and censor those who might have alternative approaches or differing interpretations, the future of medicine will be very dark. (8/8)
— Pierre Kory, MD MPA (@PierreKory) November 11, 2021
A counter-attack on the unprecedented hospital restrictions of a physicians ability to practice medicine in COVID was launched by Prof. Marik last night.
A major 1st step to restoring the critical role of expert (not "captured-agency") decision-making at the bedside. IT IS ON https://t.co/tZ6ypzAG3K
— Pierre Kory, MD MPA (@PierreKory) November 10, 2021
FLCC shared this press release:
Paul Marik, MD, one of the most highly published critical care physicians in the world and the Director of the ICU at Sentara Norfolk General Hospital, was recently told by Sentara Healthcare that he could no longer administer a range of highly effective COVID-19 treatments to critically ill patients—the same treatments he has successfully used to reduce COVID deaths in the ICU by as much as 50%. The result of the prohibition has been a sharp increase in patient mortality. Because Dr. Marik can no longer stand by while patients needlessly die without proper treatment, he has filed a lawsuit to allow him and his colleagues to administer the combination of FDA-approved drugs and other therapies that has saved thousands of critically ill COVID-19 patients in the last 18 months.
The Complaint filed today in the Circuit Court for the City of Norfolk, Virginia states that Sentara Healthcare is “preventing terminally ill COVID patients from exercising their right to choose and to receive safe, potentially life-saving treatment determined to be appropriate for them by their attending physician.” Under Virginia law, every patient has the right to receive treatment deemed appropriate for them by their attending physician, and terminally ill patients have the right to try investigational medicines that their treating physician recommends. Through
its arbitrary prohibition of the COVID-19 treatment protocol developed by Dr. Marik and his colleagues, Sentara is violating the law and unjustly depriving critically ill patients of lifesaving treatment.
“This case is about doctors, having the ability to honor their Hippocratic Oath, to follow evidence-based medicine, and to treat our patients the best we know how. Corporations and faceless bureaucrats should not be allowed to interfere with doctor-patient decisions, especially when it can result in harm or death.” according to Paul Marik, MD, chief, Division of Pulmonary & Critical Care Medicine, Eastern Virginia Medical School, who practices in the Sentara
Norfolk General Hospital. “I refuse to watch another patient die from COVID-19 knowing that I was not allowed to give them proven treatments that could have saved their life.”
According to an accompanying declaration from a renowned critical care specialist recently recognized by the United Nations for his life-saving work, Joseph Varon, MD, the COVID-19 treatment protocol developed by Dr. Marik and his colleagues, called the “MATH+ Protocol,” has achieved at least a 50% reduction in deaths from the virus in the hospitals where he serves as Chief of Staff.
“The Sentara Healthcare System’s prohibition of the MATH+ protocol is a threat to every doctor and every patient in the U.S.,” said Pierre Kory, president and chief medical officer of the Front Line COVID-19 Critical Care Alliance (FLCCC). “We know the protocol is effective. Patients who could have been saved by MATH+ are dying because of the hospital’s baseless restriction. We will continue to see more deaths that could have been prevented until the court takes action and orders the hospital to reverse course.”
The MATH+ protocol has been used all over the world to effectively treat patients with COVID19. It is generally well-tolerated with no reports of adverse medical events. In its September 27 memo to employees, Sentara Healthcare System tried to justify prohibiting many of medications in the MATH+ protocol by claiming it “is not supported in peer-reviewed, published RCTs,” (Randomized Controlled Trials). However, this claim is demonstrably false. Peer-reviewed published RCTs do support the use many of the medications Sentara has prohibited, including fluvoxamine and ivermectin.
“The FLCCC stands behind Paul 100%,” said Dr. Kory. “We take an oath as doctors to do no harm. I can’t think of a way of doing more harm to a patient than to not administer a treatment that you know can help them. No doctor should be forced to watch their patient die knowing that more could have been done to save them and that is exactly what Sentara is doing.”
WTKR 3 reported:
“Sentara Healthcare is consistently ranked among the top hospitals in the nation for quality and patient safety, and follows evidence-based protocols to treat COVID-19 as recommended by trusted agencies including the CDC, NIH and FDA. All of these agencies currently do not recommend the use of ivermectin as a treatment for COVID-19 due to a lack of evidence regarding its safety and efficacy. Sentara generates treatment guidelines by engaging multi-disciplinary groups of clinicians to review literature, care standards and provide expert advice. In most situations, physicians are able to deviate from guidelines to individualize care for patients. However, in some scenarios, treatments that may potentially harm patients or that are widely considered to be outside the standard of care may be limited.
To that end, COVID-19 treatment guidelines at Sentara have been consistently communicated to all medical staff throughout the pandemic using usual channels. The most recent guidelines generated by the multi-disciplinary group of clinicians did include, but were not limited to, guidance on the use of ivermectin. All members of the medical staff receive the same guidelines.
Of note, on Tuesday, November 9, prior to when we were informed about Dr. Marik’s lawsuit, the Journal of Intensive Care Medicine’s (JICM) editorial board retracted a recent article that Dr. Marik co-authored on the MATH+ protocol, in which ivermectin is used. Sentara Healthcare felt obligated to reach out to JICM with our concerns about Sentara Norfolk General Hospital data that the authors used to make conclusions, and provide accurate data to the Journal. After thorough review by JICM’s editorial board, the article was retracted. The Journal followed their retraction guidelines and procedures.
Sentara Healthcare is currently studying this lawsuit and offers no further comment on it at this time.”
